JP4004066B2 - プリン誘導体およびその製法 - Google Patents

プリン誘導体およびその製法 Download PDF

Info

Publication number
JP4004066B2
JP4004066B2 JP50604797A JP50604797A JP4004066B2 JP 4004066 B2 JP4004066 B2 JP 4004066B2 JP 50604797 A JP50604797 A JP 50604797A JP 50604797 A JP50604797 A JP 50604797A JP 4004066 B2 JP4004066 B2 JP 4004066B2
Authority
JP
Japan
Prior art keywords
amino
phenyl
carbamoyl
ethyl
purine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP50604797A
Other languages
English (en)
Japanese (ja)
Other versions
JPH11514336A5 (enExample
JPH11514336A (ja
Inventor
ツィンマーマン,ユルク
カプラロ,ハンス−ゲオルク
イムバッハ,パトリシア
フュレ,パスカル
Original Assignee
ノバルティス アクチエンゲゼルシャフト
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノバルティス アクチエンゲゼルシャフト filed Critical ノバルティス アクチエンゲゼルシャフト
Publication of JPH11514336A publication Critical patent/JPH11514336A/ja
Publication of JPH11514336A5 publication Critical patent/JPH11514336A5/ja
Application granted granted Critical
Publication of JP4004066B2 publication Critical patent/JP4004066B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • C07D473/02Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/16Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP50604797A 1995-11-01 1996-10-22 プリン誘導体およびその製法 Expired - Fee Related JP4004066B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CH309495 1995-11-01
CH3094/95 1995-11-01
CH2213/96 1996-09-10
CH221396 1996-09-10
PCT/EP1996/004573 WO1997016452A1 (en) 1995-11-01 1996-10-22 Purine derivatives and processes for their preparation

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2007148965A Division JP2007231023A (ja) 1995-11-01 2007-06-05 プリン誘導体およびその製法

Publications (3)

Publication Number Publication Date
JPH11514336A JPH11514336A (ja) 1999-12-07
JPH11514336A5 JPH11514336A5 (enExample) 2004-10-14
JP4004066B2 true JP4004066B2 (ja) 2007-11-07

Family

ID=25689809

Family Applications (2)

Application Number Title Priority Date Filing Date
JP50604797A Expired - Fee Related JP4004066B2 (ja) 1995-11-01 1996-10-22 プリン誘導体およびその製法
JP2007148965A Pending JP2007231023A (ja) 1995-11-01 2007-06-05 プリン誘導体およびその製法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2007148965A Pending JP2007231023A (ja) 1995-11-01 2007-06-05 プリン誘導体およびその製法

Country Status (13)

Country Link
US (1) US7091346B1 (enExample)
EP (1) EP0874846B1 (enExample)
JP (2) JP4004066B2 (enExample)
CN (1) CN1066147C (enExample)
AR (1) AR004134A1 (enExample)
AT (1) ATE236161T1 (enExample)
AU (1) AU7296896A (enExample)
BR (1) BR9611157A (enExample)
CA (1) CA2234609C (enExample)
DE (1) DE69627195T2 (enExample)
ES (1) ES2196181T3 (enExample)
PT (1) PT874846E (enExample)
WO (1) WO1997016452A1 (enExample)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2741881B1 (fr) 1995-12-01 1999-07-30 Centre Nat Rech Scient Nouveaux derives de purine possedant notamment des prorietes anti-proliferatives et leurs applications biologiques
US6794390B2 (en) * 1996-08-02 2004-09-21 Cv Therapeutics, Inc. Purine inhibitors of cyclin dependent kinase 2 & ikappabalpha
US5866702A (en) * 1996-08-02 1999-02-02 Cv Therapeutics, Incorporation Purine inhibitors of cyclin dependent kinase 2
US6790958B2 (en) * 1996-08-02 2004-09-14 Robert T. Lum Purine inhibitors of cyclin dependent kinase 2 & IKBA
AU4920397A (en) * 1996-10-11 1998-05-11 Chiron Corporation Purine inhibitors of glycogen synthase kinase 3 (gsk3)
US6432947B1 (en) * 1997-02-19 2002-08-13 Berlex Laboratories, Inc. N-heterocyclic derivatives as NOS inhibitors
JP2001516694A (ja) 1997-08-07 2001-10-02 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア プロテインキナーゼ、gプロテイン及びポリメラーゼのプリン阻害剤
US6573044B1 (en) 1997-08-07 2003-06-03 The Regents Of The University Of California Methods of using chemical libraries to search for new kinase inhibitors
CA2306082A1 (en) 1997-10-27 1999-05-06 Agouron Pharmaceuticals, Inc. Substituted 4-amino-thiazol-2-y compounds as cdks inhibitors
WO1999031072A1 (en) * 1997-12-18 1999-06-24 E.I. Du Pont De Nemours And Company Cyclohexylamine arthropodicides and fungicides
TR200002482T2 (tr) * 1998-02-26 2002-10-21 Aventis Pharmaceuticals Inc. 6,9-Diikameli 2-(Trans-(4-Aminosiklohekzil) Amino)Pürinler
US6642231B2 (en) * 1998-02-26 2003-11-04 Aventis Pharmaceuticals Inc. 6,9-disubstituted 2-[trans-(4-aminocyclohexyl)amino] purines
US6479487B1 (en) * 1998-02-26 2002-11-12 Aventis Pharmaceuticals Inc. 6, 9-disubstituted 2-[trans-(4-aminocyclohexyl)amino] purines
RU2200162C2 (ru) * 1998-02-26 2003-03-10 Авентис Фармасьютикалз Инк. 6,9-дизамещенные 2-[транс(4-аминоциклогексил)амино] пурины
US6413974B1 (en) * 1998-02-26 2002-07-02 Aventis Pharmaceuticals Inc. 6,9,-disubstituted 2-[trans-(4-aminocyclohexyl) amino] purines
CZ27399A3 (cs) * 1999-01-26 2000-08-16 Ústav Experimentální Botaniky Av Čr Substituované dusíkaté heterocyklické deriváty, způsob jejich přípravy, tyto deriváty pro použití jako léčiva, farmaceutická kompozice a kombinovaný farmaceutický přípravek tyto deriváty obsahující a použití těchto derivátů pro výrobu léčiv
GB9903762D0 (en) * 1999-02-18 1999-04-14 Novartis Ag Organic compounds
US7125875B2 (en) 1999-04-15 2006-10-24 Bristol-Myers Squibb Company Cyclic protein tyrosine kinase inhibitors
FR2793794B1 (fr) * 1999-05-21 2001-07-27 Hoechst Marion Roussel Inc Nouveaux derives de la purine, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilisation
GB9918035D0 (en) * 1999-07-30 1999-09-29 Novartis Ag Organic compounds
EP1244668B1 (en) * 2000-01-07 2006-04-05 Universitaire Instelling Antwerpen Purine derivatives, process for their preparation and use thereof
WO2001082967A1 (fr) * 2000-04-28 2001-11-08 Yamanouchi Pharmaceutical Co., Ltd. Compositions medicinales destinees a supprimer la production de ?-amyloide
US6861524B2 (en) 2000-10-31 2005-03-01 Aventis Pharmaceuticals Inc. Acyl and sulfonyl derivatives of 6,9-disubstituted 2-(trans-1,4-diaminocyclohexyl)-purines and their use as antiproliferative agents
FR2818642B1 (fr) * 2000-12-26 2005-07-15 Hoechst Marion Roussel Inc Nouveaux derives de la purine, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilistion
PE20030008A1 (es) 2001-06-19 2003-01-22 Bristol Myers Squibb Co Inhibidores duales de pde 7 y pde 4
DE60205376T2 (de) 2001-06-27 2006-04-06 Cyclacel Ltd. 2,6,9-substituierte purinderivate und ihre verwendung bei der behandlung proliferativer krankheiten
CZ294535B6 (cs) * 2001-08-02 2005-01-12 Ústav Experimentální Botaniky Avčr Heterocyklické sloučeniny na bázi N6-substituovaného adeninu, způsoby jejich přípravy, jejich použití pro přípravu léčiv, kosmetických přípravků a růstových regulátorů, farmaceutické přípravky, kosmetické přípravky a růstové regulátory tyto sloučeniny obsahující
US20040248906A1 (en) 2001-08-10 2004-12-09 Donato Nicholas J Use of c-src inhibitors alone or in combination with st1571 for the treatment of leukaemia
AU2002342051B2 (en) * 2001-10-12 2009-06-11 Irm Llc Kinase inhibitor scaffolds and methods for their preparation
GB0219052D0 (en) 2002-08-15 2002-09-25 Cyclacel Ltd New puring derivatives
GB0219054D0 (en) 2002-08-15 2002-09-25 Cyclacel Ltd New purine derivatives
CA2499593C (en) 2002-09-19 2011-08-16 Michael P. Dwyer Pyrazolopyridines as cyclin dependent kinase inhibitors
US7273864B2 (en) * 2002-10-15 2007-09-25 The Scripps Research Institute Compositions and methods for inducing osteogenesis
EP1608631A4 (en) 2003-03-28 2008-08-20 Scios Inc BICYCLIC PYRIMIDININHIBITORS OF TGF BETA
US20050288290A1 (en) * 2004-06-28 2005-12-29 Borzilleri Robert M Fused heterocyclic kinase inhibitors
US7439246B2 (en) 2004-06-28 2008-10-21 Bristol-Myers Squibb Company Fused heterocyclic kinase inhibitors
WO2007070872A1 (en) * 2005-12-15 2007-06-21 Rigel Pharmaceuticals, Inc. Kinase inhibitors and their uses
RS53588B1 (sr) 2006-12-08 2015-02-27 Irm Llc Jedinjenja i kompozicije kao inhibitori protein kinaza
BRPI0720264B1 (pt) * 2006-12-08 2022-03-03 Novartis Ag Compostos e composições como inibidores de proteína cinase
JP5703432B2 (ja) * 2007-03-28 2015-04-22 ノイロサーチ アクティーゼルスカブ プリニル誘導体及びカリウムチャネルモジュレーターとしてのそれらの使用
EP2142545A1 (en) 2007-03-28 2010-01-13 NeuroSearch A/S Purinyl derivatives and their use as potassium channel modulators
CZ302225B6 (cs) * 2007-07-04 2010-12-29 Univerzita Palackého v Olomouci Substituované 6-anilinopurinové deriváty jako inhibitory cytokinin oxidasy a prípravky obsahující tyto slouceniny
CA2720946C (en) * 2008-04-07 2013-05-28 Irm Llc Compounds and compositions as protein kinase inhibitors
EP2344501A1 (en) * 2008-09-26 2011-07-20 NeuroSearch A/S Substituted purinyl-pyrazol derivatives and their use as potassium channel modulators
US8268838B2 (en) 2008-09-26 2012-09-18 Neurosearch A/S Substituted purinyl-pyrazole derivatives and their use as potassium channel modulators
MX2013010330A (es) 2011-03-09 2014-11-26 Richard G Pestell Líneas de célula cancerosa de próstata, signaturas de gen, y usos de las mismas.
WO2013074986A1 (en) 2011-11-17 2013-05-23 Dana-Farber Cancer Institute, Inc. Inhibitors of c-jun-n-terminal kinase (jnk)
HK1209673A1 (en) 2012-05-14 2016-04-08 Prostagene Llc Using modulators of ccr5 for treating cancer
JP6223443B2 (ja) 2012-06-26 2017-11-01 サニオナ・エイピイエス フェニルトリアゾール誘導体及びgabaa受容体複合体を調節するための該フェニルトリアゾール誘導体の使用
KR101652010B1 (ko) * 2013-03-27 2016-08-29 재단법인 아산사회복지재단 p34의 발현 억제제 또는 활성 억제제를 유효성분으로 포함하는 암의 치료 또는 전이 억제용 조성물
JP6491202B2 (ja) 2013-10-18 2019-03-27 デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド サイクリン依存性キナーゼ7(cdk7)の多環阻害剤
EP3194572B1 (en) 2014-07-30 2023-10-25 Yeda Research and Development Co. Ltd. Media for culturing pluripotent stem cells
EP3236959B1 (en) 2014-12-23 2025-09-24 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)
CA2978518C (en) * 2015-03-27 2023-11-21 Nathanael S. Gray Inhibitors of cyclin-dependent kinases
JP7028766B2 (ja) 2015-09-09 2022-03-02 ダナ-ファーバー キャンサー インスティテュート, インコーポレイテッド サイクリン依存性キナーゼの阻害剤
US10722515B2 (en) 2016-09-30 2020-07-28 Sri International Dual CLK/CDK1 inhibitors for cancer treatment
WO2020005807A1 (en) 2018-06-25 2020-01-02 Dana-Farber Cancer Institute, Inc. Taire family kinase inhibitors and uses thereof
EP3914698B1 (en) 2019-01-23 2024-12-11 Yeda Research and Development Co. Ltd Culture media for pluripotent stem cells
CN120289460A (zh) * 2024-01-09 2025-07-11 中国科学院合肥物质科学研究院 含有嘌呤环的化合物及其用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3529497A1 (de) * 1985-08-17 1987-02-26 Boehringer Mannheim Gmbh N(pfeil hoch)6(pfeil hoch)-disubstituierte purinderivate, verfahren zu deren herstellung sowie diese verbindungen enthaltende arzneimittel
AU626983B2 (en) 1989-01-31 1992-08-13 Whitby Research, Inc. N6-substituted 9-methyladenines
ES2130246T3 (es) * 1992-01-06 1999-07-01 Wellcome Found Nucleosidos terapeuticos de la serie 2',3'-didesoxi-3'-fluoro-purina.
US6403599B1 (en) 1995-11-08 2002-06-11 Pfizer Inc Corticotropin releasing factor antagonists
FR2741881B1 (fr) 1995-12-01 1999-07-30 Centre Nat Rech Scient Nouveaux derives de purine possedant notamment des prorietes anti-proliferatives et leurs applications biologiques
US6107300A (en) 1996-03-27 2000-08-22 Dupont Pharmaceuticals Arylamino fused pyrimidines
US5866702A (en) 1996-08-02 1999-02-02 Cv Therapeutics, Incorporation Purine inhibitors of cyclin dependent kinase 2
US5753635A (en) 1996-08-16 1998-05-19 Berlex Laboratories, Inc. Purine derivatives and their use as anti-coagulants
AU4920397A (en) 1996-10-11 1998-05-11 Chiron Corporation Purine inhibitors of glycogen synthase kinase 3 (gsk3)
GB9903762D0 (en) * 1999-02-18 1999-04-14 Novartis Ag Organic compounds
AU2002342051B2 (en) * 2001-10-12 2009-06-11 Irm Llc Kinase inhibitor scaffolds and methods for their preparation
US7273864B2 (en) * 2002-10-15 2007-09-25 The Scripps Research Institute Compositions and methods for inducing osteogenesis

Also Published As

Publication number Publication date
AR004134A1 (es) 1998-09-30
DE69627195D1 (de) 2003-05-08
AU7296896A (en) 1997-05-22
PT874846E (pt) 2003-08-29
CN1066147C (zh) 2001-05-23
CN1202896A (zh) 1998-12-23
ATE236161T1 (de) 2003-04-15
WO1997016452A1 (en) 1997-05-09
JP2007231023A (ja) 2007-09-13
EP0874846B1 (en) 2003-04-02
ES2196181T3 (es) 2003-12-16
BR9611157A (pt) 1999-03-30
HK1016580A1 (en) 1999-11-05
EP0874846A1 (en) 1998-11-04
US7091346B1 (en) 2006-08-15
CA2234609A1 (en) 1997-05-09
JPH11514336A (ja) 1999-12-07
DE69627195T2 (de) 2004-01-29
CA2234609C (en) 2006-11-28

Similar Documents

Publication Publication Date Title
JP4004066B2 (ja) プリン誘導体およびその製法
US6180636B1 (en) Substituted pyrrolopyrimidines and processes for their preparation
DE69027562T2 (de) Xanthinverbindungen
EP0596542B1 (en) Therapeutic nucleosides
AU777571B2 (en) 8-phenyl-6,9-dihydro-(1,2,4)triazolo(3,4-i)purin-5-one derivatives
US5525607A (en) Xanthine compounds
EP1021186B1 (en) PURINE INHIBITORS OF CYCLIN DEPENDENT KINASE 2 AND IkappaB-alpha
DE60010234T2 (de) 2-amino-6-anilino-purine und deren verwendung als arzneimittel
US6794390B2 (en) Purine inhibitors of cyclin dependent kinase 2 & ikappabalpha
US5670498A (en) 8-substituted styryl xanthine derivatives
JP2002537300A5 (enExample)
EP1939199A1 (en) Novel adenine compound
HK39595A (en) Therapeutic nucleosides
CZ283721B6 (cs) Purinové deriváty a jejich farmaceutické použití
EP0099493A1 (en) Derivatives of 9-(2-hydroxyethoxymethyl)guanine
EP0559893A1 (en) Xanthine derivative
CZ292169B6 (cs) Acyklické nukleosidové deriváty, způsob jejich přípravy a farmaceutické kompozice s jejich obsahem
DE19526163A1 (de) Neue antivirale Arzneimittel, Verfahren zu ihrer Herstellung und ihre Verwendung
EP3670500A1 (en) Chemical compound, pharmaceutical composition thereof, and use and application thereof
US5061708A (en) Therapeutic guanine esters
EP0366385B1 (en) Guanine derivatives having antiviral activity and their pharmaceutically acceptable salts
HK1016580B (en) Purine derivatives and processes for their preparation
US5756735A (en) Xanthine derivatives
JP2843671B2 (ja) キサンチン誘導体
EP0556778A2 (en) Xanthine derivatives

Legal Events

Date Code Title Description
A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20060328

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20060613

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20060731

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060928

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20070206

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070605

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20070802

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20070814

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20070821

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20100831

Year of fee payment: 3

LAPS Cancellation because of no payment of annual fees